

Mechanisms of Disease: oncogene addictionâ€™”a rationale for  
cancer therapy

Nature Clinical Practice Oncology

3, 448-457

DOI: [10.1038/ncponc0558](https://doi.org/10.1038/ncponc0558)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Oncogene Addiction: Role of Signal Attenuation. <i>Developmental Cell</i> , 2006, 11, 752-754.	3.1	10
2	“Oncogenic Shock”: Turning an Activated Kinase against the Tumor Cell. <i>Cell Cycle</i> , 2006, 5, 2878-2880.	1.3	35
3	Future of molecular profiling of human hepatocellular carcinoma. <i>Future Oncology</i> , 2007, 3, 429-439.	1.1	19
4	Selective Growth Inhibition in BRAF Mutant Thyroid Cancer by the Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4712-4718.	1.8	95
5	Oncogene addiction: setting the stage for molecularly targeted cancer therapy. <i>Genes and Development</i> , 2007, 21, 3214-3231.	2.7	377
6	Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 19488-19493.	3.3	171
7	The Novel Combination of Chlorpromazine and Pentamidine Exerts Synergistic Antiproliferative Effects through Dual Mitotic Action. <i>Cancer Research</i> , 2007, 67, 11359-11367.	0.4	95
8	A Non-Genetic Basis for Cancer Progression and Metastasis: Self-Organizing Attractors in Cell Regulatory Networks. <i>Breast Disease</i> , 2007, 26, 27-54.	0.4	143
9	Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene. <i>Cell</i> , 2007, 129, 1065-1079.	13.5	538
10	Finding biomarkers of resistance to targeted cancer therapies. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 109-114.	2.2	2
11	Expanding the repertoire of RNA interference screens for developing new anticancer drug targets. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 1429-1441.	1.5	13
12	Targeted Agents: The Rules of Combination. <i>Clinical Cancer Research</i> , 2007, 13, 5232-5237.	3.2	62
13	Molecular analysis of deletions in human chromosome 3p21 and the role of resident cancer genes in disease. <i>Briefings in Functional Genomics &amp; Proteomics</i> , 2007, 6, 19-39.	3.8	63
14	Growth Factors and Oncogenes as Targets in Melanoma: Lost in Translation?. <i>Advances in Dermatology</i> , 2007, 23, 99-129.	2.0	16
15	Cancer proteomics by quantitative shotgun proteomics. <i>Molecular Oncology</i> , 2007, 1, 144-159.	2.1	70
16	Proteome informatics for cancer research: From molecules to clinic. <i>Proteomics</i> , 2007, 7, 976-991.	1.3	26
17	High-throughput oncogene mutation profiling in human cancer. <i>Nature Genetics</i> , 2007, 39, 347-351.	9.4	927
18	Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. <i>Nature Medicine</i> , 2007, 13, 1203-1210.	15.2	804

#	ARTICLE	IF	CITATIONS
19	Epidermal growth factor receptor mutations in lung cancer. <i>Nature Reviews Cancer</i> , 2007, 7, 169-181.	12.8	2,741
20	Angiogenesis: an organizing principle for drug discovery?. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 273-286.	21.5	1,960
21	Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection. <i>Cell Death and Differentiation</i> , 2007, 14, 1958-1967.	5.0	45
22	Getting it right: designing microarray (and not "microarray") comparative genomic hybridization studies for cancer research. <i>Laboratory Investigation</i> , 2007, 87, 737-754.	1.7	68
23	BCL2L2 is a probable target for novel 14q11.2 amplification detected in a non-small cell lung cancer cell line. <i>Cancer Science</i> , 2007, 98, 1070-1077.	1.7	22
24	New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. <i>Liver International</i> , 2007, 27, 174-185.	1.9	59
25	Non-random genomic instability in cancer: A fact, not an illusion. <i>Seminars in Cancer Biology</i> , 2007, 17, 1-4.	4.3	5
26	Modeling Metastatic Breast Cancer in Mice. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2007, 12, 191-203.	1.0	55
28	Current perspectives in the treatment of advanced prostate cancer. <i>Medical Oncology</i> , 2007, 24, 273-286.	1.2	13
29	Single cell cytometry of protein function in RNAi treated cells and in native populations. <i>BMC Cell Biology</i> , 2008, 9, 43.	3.0	11
30	EGFR inhibition in the treatment of non-small cell lung cancer. <i>Drug Development Research</i> , 2008, 69, 359-372.	1.4	51
31	Management of colorectal cancer: A role for genetics in prevention and treatment?. <i>Pathology Research and Practice</i> , 2008, 204, 469-477.	1.0	17
32	Tumor dormancy and oncogene addiction. <i>Apmis</i> , 2008, 116, 629-637.	0.9	33
33	Deconstructing oncogenesis. <i>Nature</i> , 2008, 453, 995-996.	13.7	9
34	New wirings in the survivin networks. <i>Oncogene</i> , 2008, 27, 6276-6284.	2.6	160
35	Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint. <i>Oncogene</i> , 2008, 27, 3935-3943.	2.6	44
36	Role of Network Branching in Eliciting Differential Short-Term Signaling Responses in the Hypersensitive Epidermal Growth Factor Receptor Mutants Implicated in Lung Cancer. <i>Biotechnology Progress</i> , 2008, 24, 540-553.	1.3	22
37	<i>ITCH</i> is a putative target for a novel 20q11.22 amplification detected in anaplastic thyroid carcinoma cells by array-based comparative genomic hybridization. <i>Cancer Science</i> , 2008, 99, 1940-1949.	1.7	26

#	ARTICLE	IF	CITATIONS
38	Direct Genetic Analysis of Single Disseminated Cancer Cells for Prediction of Outcome and Therapy Selection in Esophageal Cancer. <i>Cancer Cell</i> , 2008, 13, 441-453.	7.7	202
39	Pancreatic Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2008, 3, 157-188.	9.6	634
40	Evolving options and future challenges for targeted therapies in ErbB2 (HER2)-positive breast cancer. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 1-6.	2.2	1
41	A functional Notch-survivin gene signature in basal breast cancer. <i>Breast Cancer Research</i> , 2008, 10, R97.	2.2	106
42	Recurrent Overexpression of c-IAP2 in EBV-Associated Nasopharyngeal Carcinomas: Critical Role in Resistance to Toll-like Receptor 3-Mediated Apoptosis. <i>Neoplasia</i> , 2008, 10, 1183-IN7.	2.3	45
43	Oncogene Addiction. <i>Cancer Research</i> , 2008, 68, 3077-3080.	0.4	801
44	Cancer as robust intrinsic state of endogenous molecular-cellular network shaped by evolution. <i>Medical Hypotheses</i> , 2008, 70, 678-684.	0.8	141
45	Modeling therapy resistance in genetically engineered mouse cancer models. <i>Drug Resistance Updates</i> , 2008, 11, 51-60.	6.5	29
46	The direct molecular analysis of metastatic precursor cells in breast cancer: A chance for a better understanding of metastasis and for personalised medicine. <i>European Journal of Cancer</i> , 2008, 44, 2721-2725.	1.3	17
47	Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. <i>Current Opinion in Pharmacology</i> , 2008, 8, 393-412.	1.7	488
48	The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations. <i>Lung Cancer</i> , 2008, 60, S19-S22.	0.9	18
49	Acute lymphoblastic leukaemia. <i>Lancet, The</i> , 2008, 371, 1030-1043.	6.3	1,308
50	Molecular Dependence of Estrogen Receptor-Negative Breast Cancer on a Notch-Survivin Signaling Axis. <i>Cancer Research</i> , 2008, 68, 5273-5281.	0.4	111
51	EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story. <i>Annual Review of Medicine</i> , 2008, 59, 429-442.	5.0	152
52	Development of therapeutic approaches to "triple negative" phenotype breast cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 1123-1137.	1.5	20
53	Modern cancer drug discovery: integrating targets, technologies and treatments. , 2008, , 3-38.		4
54	Silencing c-MYC Expression by Targeting Quadruplex in P1 Promoter Using Locked Nucleic Acid Trap. <i>Biochemistry</i> , 2008, 47, 13179-13188.	1.2	33
55	Reversing Cancer From Inside and Out: Oncogene Addiction, Cellular Senescence, and the Angiogenic Switch. <i>Lymphatic Research and Biology</i> , 2008, 6, 149-154.	0.5	19

#	ARTICLE	IF	CITATIONS
56	Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase. <i>Journal of the National Cancer Institute</i> , 2008, 100, 926-939.	3.0	149
57	Expression of t-DARPP Mediates Trastuzumab Resistance in Breast Cancer Cells. <i>Clinical Cancer Research</i> , 2008, 14, 4564-4571.	3.2	47
58	Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells. <i>Cancer Research</i> , 2008, 68, 1471-1477.	0.4	383
59	Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics. <i>Circulation</i> , 2008, 118, 84-95.	1.6	323
60	Oncogene Addiction versus Oncogene Amnesia: Perhaps More than Just a Bad Habit?. <i>Cancer Research</i> , 2008, 68, 3081-3086.	0.4	90
61	Development of genomic markers that predict response to molecularly targeted antileukemic therapy. <i>Expert Opinion on Medical Diagnostics</i> , 2008, 2, 361-372.	1.6	0
62	Comparative Genomic Hybridisation Arrays: High-Throughput Tools to Determine Targeted Therapy in Breast Cancer. <i>Pathobiology</i> , 2008, 75, 63-74.	1.9	17
63	The Hsp90 molecular chaperone: an open and shut case for treatment. <i>Biochemical Journal</i> , 2008, 410, 439-453.	1.7	410
65	Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas. <i>PLoS ONE</i> , 2008, 3, e2125.	1.1	74
66	Tumor Cell Dependence on Ran-GTP Directed Mitosis. <i>Cancer Research</i> , 2008, 68, 1826-1833.	0.4	88
67	Identification of a Novel Recepteur d'Origine Nantais/c-Met Small-Molecule Kinase Inhibitor with Antitumor Activity <i>In vivo</i> . <i>Cancer Research</i> , 2008, 68, 6680-6687.	0.4	53
68	Endothelial Function of <i>von Hippel-Lindau</i> Tumor Suppressor Gene: Control of Fibroblast Growth Factor Receptor Signaling. <i>Cancer Research</i> , 2008, 68, 4649-4657.	0.4	29
69	Molecular Targeting Agents in Renal Cell Carcinoma: Present Strategies and Future Perspectives. <i>Current Pharmaceutical Design</i> , 2008, 14, 1058-1077.	0.9	6
71	mTOR Mediates Survival Signals in Malignant Mesothelioma Grown as Tumor Fragment Spheroids. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2008, 39, 576-583.	1.4	60
72	RB status governs differential sensitivity to cytotoxic and molecularly-targeted therapeutic agents. <i>Cell Cycle</i> , 2008, 7, 1095-1103.	1.3	24
73	EBV LMP2A affects LMP1-mediated NF- $\kappa$ B signaling and survival of lymphoma cells by regulating TRAF2 expression. <i>Blood</i> , 2008, 111, 3813-3820.	0.6	79
74	Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. <i>Blood</i> , 2008, 111, 1366-1377.	0.6	250
75	A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. <i>Blood</i> , 2008, 111, 2589-2596.	0.6	117

#	ARTICLE	IF	CITATIONS
76	Molecular Alterations in Prostate Cancer as Diagnostic, Prognostic, and Therapeutic Targets. <i>Advances in Anatomic Pathology</i> , 2008, 15, 319-331.	2.4	55
77	The biology and oncology of RAF-ERK signaling. , 2008, , 382-402.		0
78	HSP90 inhibitors: targeting the cancer chaperone for combinatorial blockade of oncogenic pathways. , 2008, , 305-335.		1
80	Dependence of proliferative vascular smooth muscle cells on CD98hc (4F2hc, <i>SLC3A2</i> ). <i>Journal of Experimental Medicine</i> , 2009, 206, 2397-2406.	4.2	38
81	Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2526-2536.	1.9	65
82	Targeted inhibition of Snail family zinc finger transcription factors by oligonucleotide-Co(III) Schiff base conjugate. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 13667-13672.	3.3	80
83	Technological challenges of theranostics in oncology. <i>Expert Opinion on Medical Diagnostics</i> , 2009, 3, 381-393.	1.6	12
84	Expression of the K303R Estrogen Receptor- $\beta$ Breast Cancer Mutation Induces Resistance to an Aromatase Inhibitor via Addiction to the PI3K/Akt Kinase Pathway. <i>Cancer Research</i> , 2009, 69, 4724-4732.	0.4	62
86	Inhibition of Vascular Endothelial Growth Factor Receptor Signaling in Angiogenic Tumor Vasculature. <i>Advances in Genetics</i> , 2009, 67, 1-27.	0.8	14
87	A Twist-Snail Axis Critical for TrkB-Induced Epithelial-Mesenchymal Transition-Like Transformation, Anoikis Resistance, and Metastasis. <i>Molecular and Cellular Biology</i> , 2009, 29, 3722-3737.	1.1	194
88	Cdk2 plays a critical role in hepatocyte cell cycle progression and survival in the setting of cyclin D1 expression in vivo. <i>Cell Cycle</i> , 2009, 8, 2802-2809.	1.3	36
89	Vascular Endothelial Growth Factor Receptor-1 Is Synthetic Lethal to Aberrant $\beta$ -Catenin Activation in Colon Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 7529-7537.	3.2	67
90	Changing the clinical picture of challenging tumors: tales becoming reality?. <i>Future Oncology</i> , 2009, 5, 785-802.	1.1	1
91	Recent Advances in Validating MDM2 as a Cancer Target. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2009, 9, 882-903.	0.9	42
92	Modular Protein Engineering in Emerging Cancer Therapies. <i>Current Pharmaceutical Design</i> , 2009, 15, 893-916.	0.9	38
93	Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. <i>Carcinogenesis</i> , 2009, 30, 1139-1146.	1.3	154
94	The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway. <i>Oncology</i> , 2009, 77, 57-68.	0.9	49
95	Deregulated GSK3 Sustains Gastrointestinal Cancer Cells Survival by Modulating Human Telomerase Reverse Transcriptase and Telomerase. <i>Clinical Cancer Research</i> , 2009, 15, 6810-6819.	3.2	96

#	ARTICLE	IF	CITATIONS
96	Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2509-2516.	1.9	31
97	ErbBs in lung cancer. <i>Experimental Cell Research</i> , 2009, 315, 557-571.	1.2	61
98	TGF- $\beta$ 2 enforces senescence in Myc-transformed hematopoietic tumor cells through induction of Mad1 and repression of Myc activity. <i>Experimental Cell Research</i> , 2009, 315, 3099-3111.	1.2	26
99	Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues. <i>European Journal of Pharmacology</i> , 2009, 625, 6-22.	1.7	22
100	Mammalian Target of Rapamycin: Discovery of Rapamycin Reveals a Signaling Pathway Important for Normal and Cancer Cell Growth. <i>Seminars in Oncology</i> , 2009, 36, S3-S17.	0.8	187
101	Prostate cancer regulatory networks. <i>Journal of Cellular Biochemistry</i> , 2009, 107, 845-852.	1.2	32
102	Designing nanomaterial-enhanced electrochemical immunosensors for cancer biomarker proteins. <i>Bioelectrochemistry</i> , 2009, 76, 189-194.	2.4	112
103	Novel Hsp90 partners discovered using complementary proteomic approaches. <i>Cell Stress and Chaperones</i> , 2009, 14, 629-638.	1.2	42
104	Quantitative analysis of cell signaling and drug action via mass spectrometry-based systems level phosphoproteomics. <i>Proteomics</i> , 2009, 9, 1469-1487.	1.3	34
105	Labeling TiO <sub>2</sub> Nanoparticles with Dyes for Optical Fluorescence Microscopy and Determination of TiO <sub>2</sub> DNA Nanoconjugate Stability. <i>Small</i> , 2009, 5, 1318-1325.	5.2	95
106	BH3 Mimetic ABT-737 and a Proteasome Inhibitor Synergistically Kill Melanomas through Noxa-Dependent Apoptosis. <i>Journal of Investigative Dermatology</i> , 2009, 129, 964-971.	0.3	60
107	Targeting cancer with small molecule kinase inhibitors. <i>Nature Reviews Cancer</i> , 2009, 9, 28-39.	12.8	2,278
108	Parallel progression of primary tumours and metastases. <i>Nature Reviews Cancer</i> , 2009, 9, 302-312.	12.8	985
109	Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones. <i>Oncogene</i> , 2009, 28, 3681-3688.	2.6	55
110	A critical role for choline kinase-1 in the aggressiveness of bladder carcinomas. <i>Oncogene</i> , 2009, 28, 2425-2435.	2.6	55
111	The role of molecular analysis in breast cancer. <i>Pathology</i> , 2009, 41, 77-88.	0.3	44
112	Cancer driver mutations in protein kinase genes. <i>Cancer Letters</i> , 2009, 281, 117-127.	3.2	84
113	Cancer attractors: A systems view of tumors from a gene network dynamics and developmental perspective. <i>Seminars in Cell and Developmental Biology</i> , 2009, 20, 869-876.	2.3	491

#	ARTICLE	IF	CITATIONS
114	Show me your signalingâ€” and Iâ€™ll tell you who you are. <i>Journal of Hepatology</i> , 2009, 51, 638-639.	1.8	2
115	Targeting Oncogenes with siRNAs. <i>Methods in Molecular Biology</i> , 2009, 487, 1-22.	0.4	9
116	Next generation oncology drug development: opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 259-265.	12.5	64
117	Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. <i>Journal of Neurosurgery</i> , 2009, 111, 211-218.	0.9	51
118	siRNA and miRNA Gene Silencing. <i>Methods in Molecular Biology</i> , 2009, , .	0.4	5
119	The Plasticity of Oncogene Addiction: Implications for Targeted Therapies Directed to Receptor Tyrosine Kinases. <i>Neoplasia</i> , 2009, 11, 448-IN2.	2.3	106
120	Targeted Restoration of Down-regulated DAPK2 Tumor Suppressor Activity Induces Apoptosis in Hodgkin Lymphoma Cells. <i>Journal of Immunotherapy</i> , 2009, 32, 431-441.	1.2	38
122	Microarray-Based Comparative Genomic Hybridization. , 0, , 135-161.		0
123	RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia. <i>Blood</i> , 2009, 113, 1086-1096.	0.6	35
124	Acute myeloid leukemia induced by MLL-ENL is cured by oncogene ablation despite acquisition of complex genetic abnormalities. <i>Blood</i> , 2009, 113, 4922-4929.	0.6	25
125	Effects of Treatment on Normal Tissue: Abdomen and Pelvis Paul A Hulse, Bernadette M Carrington, and M Ben Taylor. , 2009, , 1281-1307.		0
126	Clinical Development of MET Targeted Therapy For Human Cancer. <i>Current Cancer Therapy Reviews</i> , 2009, 5, 261-270.	0.2	1
127	Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis. <i>Current Pharmaceutical Design</i> , 2010, 16, 1396-1409.	0.9	11
128	Targeting the translational machinery as a novel treatment strategy for hematologic malignancies. <i>Blood</i> , 2010, 115, 2127-2135.	0.6	84
129	Mitotic recombination in haematological malignancy. <i>Advances in Enzyme Regulation</i> , 2010, 50, 96-103.	2.9	4
130	Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science. <i>International Journal of Clinical Oncology</i> , 2010, 15, 235-241.	1.0	16
131	Medical treatments: in association or alone, their role and their future perspectives. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2010, 17, 413-419.	1.4	9
132	Esophageal Adenocarcinoma: Treatment Modalities in the Era of Targeted Therapy. <i>Digestive Diseases and Sciences</i> , 2010, 55, 3304-3314.	1.1	8



#	ARTICLE	IF	CITATIONS
133	De-regulated FGF receptors as therapeutic targets in cancer. , 2010, 125, 105-117.		163
134	Statistical method on nonrandom clustering with application to somatic mutations in cancer. BMC Bioinformatics, 2010, 11, 11.	1.2	76
135	Chemosensitization of cancer cells by siRNA using targeted nanogel delivery. BMC Cancer, 2010, 10, 10.	1.1	120
136	Exploiting the balance between life and death: Targeted cancer therapy and 'œœoncogenic shock'œœ. Biochemical Pharmacology, 2010, 80, 666-673.	2.0	53
137	Inflammation and survival pathways: Chronic lymphocytic leukemia as a model system. Biochemical Pharmacology, 2010, 80, 1936-1945.	2.0	38
138	Transgenic oncogenes induce oncogene-independent cancers with individual karyotypes and phenotypes. Cancer Genetics and Cytogenetics, 2010, 200, 79-99.	1.0	28
139	An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells. Cancer Cell, 2010, 17, 298-310.	7.7	207
140	CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation. Cancer Cell, 2010, 18, 485-498.	7.7	304
141	Oncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapy. Journal of Cellular and Molecular Medicine, 2010, 14, 805-817.	1.6	3
142	Targeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib. Clinical Pharmacology and Therapeutics, 2010, 87, 543-552.	2.3	170
143	Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal. Nature, 2010, 464, 436-440.	13.7	245
144	OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature, 2010, 467, 86-90.	13.7	877
145	Towards patient-based cancer therapeutics. Nature Biotechnology, 2010, 28, 904-906.	9.4	65
146	Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nature Reviews Cancer, 2010, 10, 241-253.	12.8	506
147	MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. Genes and Cancer, 2010, 1, 597-604.	0.6	105
148	Fibroblasts associated with cancer cells keep enhanced migration activity after separation from cancer cells: A novel character of tumor educated fibroblasts. International Journal of Oncology, 2010, 37, 317-25.	1.4	25
149	Molecular Therapy for Rhabdomyosarcoma. , 2010, , 425-458.		0
150	Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers. Biomarkers in Medicine, 2010, 4, 149-170.	0.6	7

#	ARTICLE	IF	CITATIONS
151	Translational research in oncology: key bottlenecks and new paradigms. <i>Expert Reviews in Molecular Medicine</i> , 2010, 12, e32.	1.6	12
152	p27Kip1 Mediates Addiction of Ovarian Cancer Cells to MYCC (c-MYC) and Their Dependence on MYC Paralogs. <i>Journal of Biological Chemistry</i> , 2010, 285, 32529-32538.	1.6	20
153	Quantitative Proteomics Discloses MET Expression in Mitochondria as a Direct Target of MET Kinase Inhibitor in Cancer Cells. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 2629-2641.	2.5	22
154	Biomarkers in cancer micrometastasis: where are we at?. <i>Bioanalysis</i> , 2010, 2, 881-899.	0.6	9
155	Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy. <i>Acta Pharmacologica Sinica</i> , 2010, 31, 1181-1188.	2.8	41
156	Chemistry and Pharmacology of Rapamycin and Its Derivatives. <i>The Enzymes</i> , 2010, , 329-366.	0.7	6
157	It's Diagnostics, Stupid. <i>Cell</i> , 2010, 141, 13-17.	13.5	40
158	Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer. <i>Analyst</i> , The, 2010, 135, 2496.	1.7	469
159	Small-molecule signal-transduction inhibitors: targeted therapeutic agents for single-gene disorders. <i>Journal of Medical Genetics</i> , 2010, 47, 145-149.	1.5	4
162	Targeting cancer with phosphodiesterase inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 117-131.	1.9	123
163	Identification and Characterization of KCASH2 and KCASH3, 2 Novel Cullin3 Adaptors Suppressing Histone Deacetylase and Hedgehog Activity in Medulloblastoma. <i>Neoplasia</i> , 2011, 13, 374-IN23.	2.3	82
164	Regulation and function of miRNA-21 in health and disease. <i>RNA Biology</i> , 2011, 8, 706-713.	1.5	499
165	Metastasis-suppressor genes in clinical practice: lost in translation?. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 333-342.	12.5	48
166	Orphan Nuclear Receptors. , 2011, , 2656-2661.		0
167	Role of Genotyping in Non-Small Cell Lung Cancer Treatment. <i>Drugs</i> , 2011, 71, 2231-2246.	4.9	23
169	Oncogene addiction in gliomas: Implications for molecular targeted therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011, 30, 58.	3.5	33
170	Biological Markers. , 2011, , 404-404.		0
171	Oculodermal Melanocytosis. , 2011, , 2597-2598.		0

#	ARTICLE	IF	CITATIONS
172	Tailoring Tyrosine Kinase Inhibitors to Fit the Lung Cancer Genome. <i>Translational Oncology</i> , 2011, 4, 59-70.	1.7	11
173	Targeted Therapies. , 2011, , .		4
174	Survivin Silencing as a Promising Strategy To Enhance the Sensitivity of Cancer Cells to Chemotherapeutic Agents. <i>Molecular Pharmaceutics</i> , 2011, 8, 1120-1131.	2.3	50
175	BrdU. , 2011, , 485-485.		0
176	Pathobiology of acute lymphoblastic leukemia. <i>Seminars in Diagnostic Pathology</i> , 2011, 28, 124-134.	1.0	11
177	Targeting Angiogenesis in Childhood Sarcomas. <i>Sarcoma</i> , 2011, 2011, 1-10.	0.7	9
178	Protease addiction and synthetic lethality in cancer. <i>Frontiers in Oncology</i> , 2011, 1, 25.	1.3	17
179	Systems Biology Modeling Reveals a Possible Mechanism of the Tumor Cell Death upon Oncogene Inactivation in EGFR Addicted Cancers. <i>PLoS ONE</i> , 2011, 6, e28930.	1.1	9
180	Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway. <i>PLoS ONE</i> , 2011, 6, e28973.	1.1	196
181	Cyclin D as a therapeutic target in cancer. <i>Nature Reviews Cancer</i> , 2011, 11, 558-572.	12.8	1,159
182	C10ORF97 is a novel tumor-suppressor gene of non-small-cell lung cancer and a functional variant of this gene increases the risk of non-small-cell lung cancer. <i>Oncogene</i> , 2011, 30, 4107-4117.	2.6	5
183	The E2A-HLF oncogenic fusion protein acts through Lmo2 and Bcl-2 to immortalize hematopoietic progenitors. <i>Leukemia</i> , 2011, 25, 321-330.	3.3	36
184	Widening the Path to Personalized Medicine. <i>Clinical and Translational Science</i> , 2011, 4, 392-394.	1.5	8
185	Analysis of cancer signaling networks by systems biology to develop therapies. <i>Seminars in Cancer Biology</i> , 2011, 21, 200-206.	4.3	28
186	On the intrinsic inevitability of cancer: From foetal to fatal attraction. <i>Seminars in Cancer Biology</i> , 2011, 21, 183-199.	4.3	73
187	Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence. <i>Seminars in Cancer Biology</i> , 2011, 21, 367-376.	4.3	119
188	Astrocyte elevated gene-1 (AEG-1): A multifunctional regulator of normal and abnormal physiology. , 2011, 130, 1-8.		111
189	Choosing between glycolysis and oxidative phosphorylation: A tumor's dilemma?. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2011, 1807, 552-561.	0.5	407

#	ARTICLE	IF	CITATIONS
190	Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling. <i>Journal of Clinical Oncology</i> , 2011, 29, 3085-3096.	0.8	890
191	TNF-blockade in patients with advanced hormone refractory prostate cancer. <i>Investigational New Drugs</i> , 2011, 29, 192-194.	1.2	5
192	Molecular oncology of lung cancer. <i>General Thoracic and Cardiovascular Surgery</i> , 2011, 59, 527-537.	0.4	60
193	Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. <i>EMBO Molecular Medicine</i> , 2011, 3, 623-636.	3.3	218
194	Recent progress and clinical importance on pharmacogenetics in cancer therapy. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 1621-32.	1.4	10
195	The Molecular Basis of Sarcoma. <i>Sarcoma</i> , 2011, 2011, 1-3.	0.7	2
196	c-Myc induction of programmed cell death may contribute to carcinogenesis. <i>Cancer Biology and Therapy</i> , 2011, 11, 615-626.	1.5	52
197	Scanning for oncogene addiction. <i>Science-Business EXchange</i> , 2011, 4, 1195-1195.	0.0	0
198	An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. <i>Genes and Development</i> , 2011, 25, 1628-1640.	2.7	242
199	Oncogenic MAP2K1 mutations in human epithelial tumors. <i>Carcinogenesis</i> , 2012, 33, 956-961.	1.3	38
200	Human Gene Control by Vital Oncogenes: Revisiting a Theoretical Model and Its Implications for Targeted Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2012, 13, 316-335.	1.8	11
201	Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E3395-404.	3.3	70
202	Remarkable Tumor Response to Crizotinib in a 14-Year-Old Girl With ALK-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, e147-e150.	0.8	47
203	Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of Action. <i>Current Medicinal Chemistry</i> , 2012, 19, 5705-5725.	1.2	56
204	Small Molecule Kinase Inhibitors as Anti-Cancer Therapeutics. <i>Mini-Reviews in Medicinal Chemistry</i> , 2012, 12, 399-411.	1.1	50
205	Too much or too little. <i>Cell Cycle</i> , 2012, 11, 3147-3148.	1.3	4
206	Complementary combinations: what treatments will become key to the battle against acute myelogenous leukemia?. <i>Expert Review of Hematology</i> , 2012, 5, 475-478.	1.0	3
207	Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity. <i>Cancer Biology and Therapy</i> , 2012, 13, 369-378.	1.5	22

#	ARTICLE	IF	CITATIONS
208	Selective requirement for Mediator MED23 in Ras-active lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2813-22.	3.3	46
209	EGFR Gene Mutation Study in Cytology Specimens. Acta Cytologica, 2012, 56, 661-668.	0.7	17
210	ABT-737 synergizes with Bortezomib to kill melanoma cells. Biology Open, 2012, 1, 92-100.	0.6	37
211	Using modern molecular markers to tailor breast cancer treatment: a new era for personalized medicine. Breast Cancer Management, 2012, 1, 105-108.	0.2	2
212	Hsp27 silencing coordinately inhibits proliferation and promotes Fas-induced apoptosis by regulating the PEA-15 molecular switch. Cell Death and Differentiation, 2012, 19, 990-1002.	5.0	45
213	Cancer Vulnerabilities Unveiled by Genomic Loss. Cell, 2012, 150, 842-854.	13.5	209
214	SCF <sup>2</sup> -TRCP suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. Journal of Experimental Medicine, 2012, 209, 1289-1307.	4.2	85
215	Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors. Molecular BioSystems, 2012, 8, 2645.	2.9	11
216	Identification of Small Molecule Proliferating Cell Nuclear Antigen (PCNA) Inhibitor That Disrupts Interactions with PIP-box Proteins and Inhibits DNA Replication. Journal of Biological Chemistry, 2012, 287, 14289-14300.	1.6	109
217	Meta-analysis of Phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer. Hpb, 2012, 14, 260-268.	0.1	19
218	Dysregulation of fatty acid synthesis and glycolysis in non-Hodgkin lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 11818-11823.	3.3	143
219	Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Proliferation, 2012, 45, 487-498.	2.4	1,120
220	Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer. Clinical Cancer Research, 2012, 18, 1855-1862.	3.2	371
221	Functional drug-gene interactions in lung cancer. Expert Review of Molecular Diagnostics, 2012, 12, 291-302.	1.5	7
222	The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. Lung Cancer, 2012, 75, 161-166.	0.9	45
223	Visceral obesity, metabolic syndrome, insulin resistance and cancer. Proceedings of the Nutrition Society, 2012, 71, 181-189.	0.4	214
224	Fractional proliferation: a method to deconvolve cell population dynamics from single-cell data. Nature Methods, 2012, 9, 923-928.	9.0	104
226	From genes to drugs: targeted strategies for melanoma. Nature Reviews Cancer, 2012, 12, 349-361.	12.8	323

#	ARTICLE	IF	CITATIONS
227	mCOPA: analysis of heterogeneous features in cancer expression data. <i>Journal of Clinical Bioinformatics</i> , 2012, 2, 22.	1.2	20
228	Distinct Pathologic Roles for Glycogen Synthase Kinase 3 $\beta$ in Colorectal Cancer Progression. , 2012, , .		2
229	Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine. <i>OncoTargets and Therapy</i> , 2012, 5, 21.	1.0	15
230	The cell cycle and cancer. <i>Journal of Pathology</i> , 2012, 226, 352-364.	2.1	533
231	Zinc supplementation augments <i>in vivo</i> antitumor effect of chemotherapy by restoring p53 function. <i>International Journal of Cancer</i> , 2012, 131, E562-8.	2.3	49
232	Epidermal growth factor receptor and <i>K-Ras</i> mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors. <i>Cancer</i> , 2012, 118, 3993-4003.	2.0	39
233	Defining the expressed breast cancer kinome. <i>Cell Research</i> , 2012, 22, 620-623.	5.7	23
234	Optimizing targeted cancer therapy: Towards clinical application of systems biology approaches. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 171-186.	2.0	19
235	Biomarkers of cell death applicable to early clinical trials. <i>Experimental Cell Research</i> , 2012, 318, 1252-1259.	1.2	17
236	A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton. <i>Investigational New Drugs</i> , 2012, 30, 490-507.	1.2	11
237	Cancer Pain. , 2013, , .		9
238	Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation. <i>Cancer</i> , 2013, 119, 3043-3051.	2.0	19
239	Targeting Gain of Function and Resistance Mutations in Abl and KIT by Hybrid Compound Design. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 5757-5772.	2.9	17
240	Utilizing protein structure to identify non-random somatic mutations. <i>BMC Bioinformatics</i> , 2013, 14, 190.	1.2	52
241	Impact of Genetic Targets on Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2013, 779, v-vi.	0.8	1
242	Targeting survivin in cancer. <i>Cancer Letters</i> , 2013, 332, 225-228.	3.2	156
243	Sensitive detection of protein and miRNA cancer biomarkers using silicon-based photonic crystals and a resonance coupling laser scanning platform. <i>Lab on A Chip</i> , 2013, 13, 4053.	3.1	58
244	Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 13481-13486.	3.3	147

#	ARTICLE	IF	CITATIONS
245	A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. <i>Carcinogenesis</i> , 2013, 34, 725-738.	1.3	86
246	<i>ALK</i> Rearrangements Are Mutually Exclusive with Mutations in <i>EGFR</i> or <i>KRAS</i> : An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 4273-4281.	3.2	521
247	Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch. <i>Cancer and Metastasis Reviews</i> , 2013, 32, 723-761.	2.7	52
248	Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. <i>CNS Oncology</i> , 2013, 2, 49-65.	1.2	116
249	The role of afatinib in the management of non-small cell lung carcinoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1529-1539.	1.5	4
250	A novel imidazopyridine derivative, HS-106, induces apoptosis of breast cancer cells and represses angiogenesis by targeting the PI3K/mTOR pathway. <i>Cancer Letters</i> , 2013, 329, 59-67.	3.2	34
251	Genetics and pharmacogenomics of diffuse gliomas. , 2013, 137, 78-88.		7
252	MET As a Possible Target for Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1089-1096.	0.8	173
253	Somatic evolution of head and neck cancer – Biological robustness and latent vulnerability. <i>Molecular Oncology</i> , 2013, 7, 14-28.	2.1	18
254	Nouveaux médicaments anticancéreux pour les enfants et les adolescents: où en sommes-nous en Europe?. <i>Revue D'Oncologie Hématologie Pédiatrique</i> , 2013, 1, 56-62.	0.1	0
255	Targeting MET: why, where and how?. <i>Current Opinion in Pharmacology</i> , 2013, 13, 511-518.	1.7	41
256	Translational Control in Cancer Etiology. <i>Cold Spring Harbor Perspectives in Biology</i> , 2013, 5, a012336-a012336.	2.3	294
257	Genetic Targets in Pediatric Acute Lymphoblastic Leukemia. <i>Advances in Experimental Medicine and Biology</i> , 2013, 779, 327-340.	0.8	17
258	Somatic changes in primary liver cancer in Russia: A pilot study. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2013, 755, 90-99.	0.9	11
259	ACK1 tyrosine kinase: Targeted inhibition to block cancer cell proliferation. <i>Cancer Letters</i> , 2013, 338, 185-192.	3.2	53
260	Oncogene and non-oncogene addiction in inflammation-associated cancers. <i>Future Oncology</i> , 2013, 9, 561-573.	1.1	10
261	Identification of Interconnected Markers for T-Cell Acute Lymphoblastic Leukemia. <i>BioMed Research International</i> , 2013, 2013, 1-20.	0.9	5
262	Systems Modeling of Anti-apoptotic Pathways in Prostate Cancer: Psychological Stress Triggers a Synergism Pattern Switch in Drug Combination Therapy. <i>PLoS Computational Biology</i> , 2013, 9, e1003358.	1.5	36

#	ARTICLE	IF	CITATIONS
263	Predictors of Biomarkers Guiding Targeted Therapeutic Strategies in Locally Advanced Lung Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2013, 19, 263-271.	1.0	4
264	Cell-Autonomous and Non-Cell-Autonomous Mechanisms of HGF/MET-Driven Resistance to Targeted Therapies: From Basic Research to a Clinical Perspective. <i>Cancer Discovery</i> , 2013, 3, 978-992.	7.7	84
265	the 11q13-q14 amplicon: Clinicopathological correlations and potential drivers. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 333-355.	1.5	70
266	The roles of PIKE in tumorigenesis. <i>Acta Pharmacologica Sinica</i> , 2013, 34, 991-997.	2.8	10
267	Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 7413-7417.	3.3	149
268	Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors. <i>FASEB Journal</i> , 2013, 27, 4279-4293.	0.2	29
269	sbv IMPROVER Diagnostic Signature Challenge. <i>Systems Biomedicine (Austin, Tex )</i> , 2013, 1, 196-207.	0.7	6
271	Mechanisms and insights into drug resistance in cancer. <i>Frontiers in Pharmacology</i> , 2013, 4, 28.	1.6	503
272	Discovering Some Novel 7-Chloroquinolines Carrying a Biologically Active Benzenesulfonamide Moiety as a New Class of Anticancer Agents. <i>Chemical and Pharmaceutical Bulletin</i> , 2013, 61, 50-58.	0.6	30
273	Lapatinib-Binding Protein Kinases in the African Trypanosome: Identification of Cellular Targets for Kinase-Directed Chemical Scaffolds. <i>PLoS ONE</i> , 2013, 8, e56150.	1.1	36
274	Identifying Resistance Mechanisms against Five Tyrosine Kinase Inhibitors Targeting the ERBB/RAS Pathway in 45 Cancer Cell Lines. <i>PLoS ONE</i> , 2013, 8, e59503.	1.1	21
275	NOTCH3 Is a Prognostic Factor That Promotes Glioma Cell Proliferation, Migration and Invasion via Activation of CCND1 and EGFR. <i>PLoS ONE</i> , 2013, 8, e77299.	1.1	47
276	A view on EGFR-targeted therapies from the oncogene-addiction perspective. <i>Frontiers in Pharmacology</i> , 2013, 4, 53.	1.6	41
277	From Gliomagenesis to Multimodal Therapeutic Approaches into High-Grade Glioma Treatment. , 0, , .		0
278	Protein Kinase Inhibitors for Clinical Targeted Cancer Treatment. <i>Clinical Pharmacology &amp; Biopharmaceutics</i> , 2013, 02, .	0.2	2
279	Model Systems Facilitating an Understanding of Mechanisms for Oncogene Amplification. , 0, , .		0
280	Exome sequencing reveals a potential mutational trajectory and treatments for a specific pancreatic cancer patient. <i>OncoTargets and Therapy</i> , 2014, 7, 655.	1.0	7
281	Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. <i>OncoTargets and Therapy</i> , 2014, 7, 1689.	1.0	65



#	ARTICLE	IF	CITATIONS
282	Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer. <i>Oncotarget</i> , 2014, 5, 9227-9238.	0.8	93
283	Cholesterol depletion by methyl- $\beta$ -cyclodextrin augments tamoxifen induced cell death by enhancing its uptake in melanoma. <i>Molecular Cancer</i> , 2014, 13, 204.	7.9	92
284	Proteomic analysis of phosphorylation in cancer. <i>Expert Review of Proteomics</i> , 2014, 11, 259-267.	1.3	44
285	2.3 Cell Lines for Vaccine Production. , 2014, , 60-86.		0
286	Resistance to dual blockade of the kinases PI3K and mTOR in <i>KRAS</i> -mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. <i>Science Signaling</i> , 2014, 7, ra107.	1.6	30
287	Proteomic Profiling Identified Multiple Short-lived Members of the Central Proteome as the Direct Targets of the Addicted Oncogenes in Cancer Cells. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 49-62.	2.5	12
288	Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine. <i>E cancer medical science</i> , 2014, 8, 479.	0.6	44
289	EGFR signaling and autophagy dependence for growth, survival, and therapy resistance. <i>Cell Cycle</i> , 2014, 13, 42-51.	1.3	97
290	G-quadruplex ligands: Mechanisms of anticancer action and target binding. <i>Molecular Biology</i> , 2014, 48, 778-794.	0.4	24
292	A graph theoretic approach to utilizing protein structure to identify non-random somatic mutations. <i>BMC Bioinformatics</i> , 2014, 15, 86.	1.2	26
293	A novel lead compound CM-118. <i>Cancer Biology and Therapy</i> , 2014, 15, 721-734.	1.5	14
294	MEK Inhibitor for Gastric Cancer with <i>MEK1</i> Gene Mutations. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 3098-3106.	1.9	16
295	Progress of cancer research on astrocyte elevated gene-1/Metadherin (Review). <i>Oncology Letters</i> , 2014, 8, 493-501.	0.8	48
296	Activated Hepatic Stellate Cells Are Dependent on Self-collagen, Cleaved by Membrane Type 1 Matrix Metalloproteinase for Their Growth. <i>Journal of Biological Chemistry</i> , 2014, 289, 20209-20221.	1.6	29
297	Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review). <i>Molecular and Clinical Oncology</i> , 2014, 2, 175-181.	0.4	48
298	A New Hope in Immunotherapy for Malignant Gliomas: Adoptive T Cell Transfer Therapy. <i>Journal of Immunology Research</i> , 2014, 2014, 1-16.	0.9	24
299	Exploiting Cancer Dependence on Molecular Chaperones. , 2014, , 239-274.		1
300	Synergistic Cooperation Between Sunitinib and Cisplatin Promotes Apoptotic Cell Death in Human Medullary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 498-509.	1.8	23

#	ARTICLE	IF	CITATIONS
301	Increase of <i>MET</i> gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence. <i>Molecular Oncology</i> , 2014, 8, 1561-1574.	2.1	15
302	Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. <i>Trends in Genetics</i> , 2014, 30, 326-339.	2.9	230
303	Systems Biology of Pancreatic Cancer Stem Cells. , 2014, , 297-322.		0
304	A spatial simulation approach to account for protein structure when identifying non-random somatic mutations. <i>BMC Bioinformatics</i> , 2014, 15, 231.	1.2	21
305	The role of HER3 in gastric cancer. <i>Biomedicine and Pharmacotherapy</i> , 2014, 68, 809-812.	2.5	16
306	Targeted therapies in cancer and mechanisms of resistance. <i>Journal of Molecular Medicine</i> , 2014, 92, 677-679.	1.7	6
307	Epidermal growth factor receptor mutations in lung adenocarcinoma. <i>Laboratory Investigation</i> , 2014, 94, 129-137.	1.7	188
308	Identification of Type II and III DDR2 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 4252-4262.	2.9	34
309	Steering tumor progression through the transcriptional response to growth factors and stroma. <i>FEBS Letters</i> , 2014, 588, 2407-2414.	1.3	7
310	FGF Receptors: Cancer Biology and Therapeutics. <i>Medicinal Research Reviews</i> , 2014, 34, 280-300.	5.0	448
311	The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts. <i>Haematologica</i> , 2014, 99, 858-864.	1.7	48
312	17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition. <i>International Journal of Molecular Medicine</i> , 2015, 36, 424-432.	1.8	10
313	PIWIL2 promotes progression of non-small cell lung cancer by inducing CDK2 and Cyclin A expression. <i>Journal of Translational Medicine</i> , 2015, 13, 301.	1.8	42
314	Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. <i>Oncotarget</i> , 2015, 6, 20785-20800.	0.8	112
315	A Quantitative Systems Pharmacology Perspective on Cancer Immunology. <i>Processes</i> , 2015, 3, 235-256.	1.3	8
316	Etio-Pathogenesis III. , 2015, , 153-184.		0
317	Clinical Trials of Mitotic Kinesin Inhibitors. , 2015, , 63-76.		1
318	Etio-pathogenesis I. , 2015, , 89-123.		1

#	ARTICLE	IF	CITATIONS
319	12-Deoxyphorbol 13-palmitate inhibits the expression of VEGF and HIF-1 $\alpha$ in MCF-7 cells by blocking the PI3K/Akt/mTOR signaling pathway. <i>Oncology Reports</i> , 2015, 34, 1755-1760.	1.2	29
320	HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. <i>Breast Cancer Research</i> , 2015, 17, 149.	2.2	42
322	Gefitinib: a review of its use in adults with advanced non-small cell lung cancer. <i>Targeted Oncology</i> , 2015, 10, 153-170.	1.7	51
323	Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer. <i>European Journal of Pharmacology</i> , 2015, 754, 82-91.	1.7	31
324	Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein. <i>Clinical and Translational Immunology</i> , 2015, 4, e30.	1.7	39
325	Lanthanum strontium manganese oxide (LSMO) nanoparticles: a versatile platform for anticancer therapy. <i>RSC Advances</i> , 2015, 5, 60254-60263.	1.7	30
326	Understanding next generation sequencing in oncology: A guide for oncologists. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 463-474.	2.0	38
327	The PI3K/AKT/mTOR interactive pathway. <i>Molecular BioSystems</i> , 2015, 11, 1946-1954.	2.9	379
328	A Novel Therapeutic Combination Sequentially Targeting Aurora B and Bcl-xL in Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 3079-3086.	0.7	8
329	Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 1386-1394.	1.4	44
330	Inhibition of Oncogenic Epidermal Growth Factor Receptor Kinase Triggers Release of Exosome-like Extracellular Vesicles and Impacts Their Phosphoprotein and DNA Content. <i>Journal of Biological Chemistry</i> , 2015, 290, 24534-24546.	1.6	99
331	Directly targeting transcriptional dysregulation in cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 686-694.	12.8	95
332	Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs. <i>Pharmacological Research</i> , 2015, 102, 123-131.	3.1	51
333	Next-generation sequencing and personalized genomic medicine in hepatobiliary malignancies. <i>Hepatic Oncology</i> , 2015, 2, 359-370.	4.2	0
335	Ionizing radiation-induced oxidative stress, epigenetic changes and genomic instability: The pivotal role of mitochondria. <i>International Journal of Radiation Biology</i> , 2015, 91, 1-12.	1.0	166
336	BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma. <i>Oncotarget</i> , 2016, 7, 43504-43517.	0.8	35
337	EGFR Signaling in Liver Diseases. <i>International Journal of Molecular Sciences</i> , 2016, 17, 30.	1.8	161
338	Targeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and Treatment. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1552.	1.8	27

#	ARTICLE	IF	CITATIONS
339	Functional genomics reveals that tumors with activating phosphoinositide 3-kinase mutations are dependent on accelerated protein turnover. <i>Genes and Development</i> , 2016, 30, 2684-2695.	2.7	11
340	Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic <i>HER4</i> Mutations in HNSCC. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1988-1997.	1.9	16
341	HSP90 Inhibition Suppresses PGE2 Production via Modulating COX-2 and 15-PGDH Expression in HT-29 Colorectal Cancer Cells. <i>Inflammation</i> , 2016, 39, 1116-23.	1.7	13
342	Integration of chinese medicine with western medicine could lead to future medicine: molecular module medicine. <i>Chinese Journal of Integrative Medicine</i> , 2016, 22, 243-250.	0.7	5
343	Metabolism in Cancer. <i>Recent Results in Cancer Research</i> , 2016, , .	1.8	5
344	Metabolic Features of Cancer Treatment Resistance. <i>Recent Results in Cancer Research</i> , 2016, 207, 135-156.	1.8	34
345	Regulatory non-coding RNA: new instruments in the orchestration of cell death. <i>Cell Death and Disease</i> , 2016, 7, e2333-e2333.	2.7	101
346	High Energy Particle Radiation-associated Oncogenic Transformation in Normal Mice: Insight into the Connection between Activation of Oncotargets and Oncogene Addiction. <i>Scientific Reports</i> , 2016, 6, 37623.	1.6	11
348	Nanotechnology in Gene Delivery: Pharmacokinetic and Pharmacodynamic Perspectives. , 2016, , 295-326.		2
349	MiR-29b suppresses the proliferation and migration of osteosarcoma cells by targeting CDK6. <i>Protein and Cell</i> , 2016, 7, 434-444.	4.8	61
350	Leveraging protein quaternary structure to identify oncogenic driver mutations. <i>BMC Bioinformatics</i> , 2016, 17, 137.	1.2	8
351	How Can Gastric Cancer Molecular Profiling Guide Future Therapies?. <i>Trends in Molecular Medicine</i> , 2016, 22, 534-544.	3.5	50
352	Photosensitizers binding to nucleic acids as anticancer agents. <i>Future Medicinal Chemistry</i> , 2016, 8, 179-194.	1.1	22
353	Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype. <i>Nature Communications</i> , 2016, 7, 10180.	5.8	142
354	Different Facets of Copy Number Changes: Permanent, Transient, and Adaptive. <i>Molecular and Cellular Biology</i> , 2016, 36, 1050-1063.	1.1	47
355	Identification of PRKDC (Protein Kinase, DNA-Activated, Catalytic Polypeptide) as an essential gene for colorectal cancer (CRCs) cells. <i>Gene</i> , 2016, 584, 90-96.	1.0	31
356	A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 571-578.	1.0	31
357	An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer. <i>Cancer Biology and Therapy</i> , 2016, 17, 346-354.	1.5	58

#	ARTICLE	IF	CITATIONS
358	G4 DNA in ras genes and its potential in cancer therapy. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2016, 1859, 663-674.	0.9	45
359	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2016, 17, 367-377.	5.1	444
361	Cancer Drug Resistance: A Brief Overview from a Genetic Viewpoint. <i>Methods in Molecular Biology</i> , 2016, 1395, 1-18.	0.4	84
362	Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2). <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 521-544.	1.4	21
363	The Role of Energy Balance in Cancer Prevention. , 2016, , 321-337.		0
364	The application of antitumor drug-targeting models on liver cancer. <i>Drug Delivery</i> , 2016, 23, 1667-1675.	2.5	3
365	Electrochemistry-based approaches to low cost, high sensitivity, automated, multiplexed protein immunoassays for cancer diagnostics. <i>Analyst, The</i> , 2016, 141, 536-547.	1.7	57
367	Molecular Pathogenesis and Targeted Therapy of Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 197-205.	0.7	39
369	Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study. <i>Investigational New Drugs</i> , 2017, 35, 451-462.	1.2	44
370	USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer. <i>Journal of Biological Chemistry</i> , 2017, 292, 4164-4175.	1.6	37
371	Transcriptional Addiction in Cancer. <i>Cell</i> , 2017, 168, 629-643.	13.5	843
372	Synthesis and structure of dihydroberberine nitroaryl derivatives " potential ligands for G-quadruplexes. <i>Chemistry of Heterocyclic Compounds</i> , 2017, 53, 335-340.	0.6	10
373	p53 and its mutants on the slippery road from stemness to carcinogenesis. <i>Carcinogenesis</i> , 2017, 38, 347-358.	1.3	28
374	Drugging the 'undruggable' cancer targets. <i>Nature Reviews Cancer</i> , 2017, 17, 502-508.	12.8	620
375	Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A. <i>BMC Cancer</i> , 2017, 17, 281.	1.1	31
376	Harnessing benefit from targeting tumor associated carbohydrate antigens. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 323-331.	1.4	10
377	An update on the implications of cyclin D1 in oral carcinogenesis. <i>Oral Diseases</i> , 2017, 23, 897-912.	1.5	74
378	Timeline metastatic progression: in the wake of the "seed and soil" theory. <i>Medical Oncology</i> , 2017, 34, 185.	1.2	17

#	ARTICLE	IF	CITATIONS
379	Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors. <i>Cancer Research</i> , 2017, 77, 5614-5627.	0.4	31
380	Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents. <i>European Journal of Medicinal Chemistry</i> , 2017, 142, 271-289.	2.6	167
381	UV-Induced Molecular Signaling Differences in Melanoma and Non-melanoma Skin Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 996, 27-40.	0.8	94
382	From bench to clinical trials the EORTC experience in biology-based clinical cancer research. <i>Journal of the Egyptian National Cancer Institute</i> , 2017, 29, 171-176.	0.6	0
383	Mouse Models of Breast Cancer: Deceptions that Reveal the Truth. , 2017, , 49-60.		0
384	Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 621-630.	0.2	5
385	Phosphorylation of the C-Raf N Region Promotes Raf Dimerization. <i>Molecular and Cellular Biology</i> , 2017, 37, .	1.1	20
386	PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models. <i>Molecular Cancer</i> , 2017, 16, 93.	7.9	18
387	Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC). <i>Seminars in Cancer Biology</i> , 2017, 45, 36-49.	4.3	11
388	Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview. <i>Medicinal Research Reviews</i> , 2017, 37, 314-367.	5.0	65
390	Adult Stem Cells and Anticancer Therapy. <i>Advances in Molecular Toxicology</i> , 2017, 11, 123-202.	0.4	9
391	Targeting Strategies for the Combination Treatment of Cancer Using Drug Delivery Systems. <i>Pharmaceutics</i> , 2017, 9, 46.	2.0	116
392	ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology. <i>Cancers</i> , 2017, 9, 33.	1.7	25
393	The Dual Roles of MYC in Genomic Instability and Cancer Chemoresistance. <i>Genes</i> , 2017, 8, 158.	1.0	36
394	Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine. <i>BioMed Research International</i> , 2017, 2017, 1-18.	0.9	40
395	Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib. <i>Clinical and Translational Medicine</i> , 2017, 6, 37.	1.7	19
396	Prognostic implications of phosphatidylinositol 3-kinase/AKT signaling pathway activation in gastric carcinomas. <i>Archives of Medical Science</i> , 2017, 6, 1262-1268.	0.4	10
397	A mathematical theory of the transcription repression (TR) therapy of cancer - whether and how it may work. <i>Oncotarget</i> , 2017, 8, 38642-38649.	0.8	3

#	ARTICLE	IF	CITATIONS
398	Toward an integrated map of genetic interactions in cancer cells. <i>Molecular Systems Biology</i> , 2018, 14, e7656.	3.2	64
399	Homoharringtonine could induce quick protein synthesis of PSMD11 through activating MEK1/ERK1/2 signaling pathway in pancreatic cancer cells. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 6644-6656.	1.2	21
400	Resistance of Lung Cancer to Kinase Inhibitors Specific to EGFR or ALK. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2018, , 29-49.	0.1	0
401	Pharmacological Review on Asiatic Acid and Its Derivatives: A Potential Compound. <i>SLAS Technology</i> , 2018, 23, 111-127.	1.0	60
402	The classification of lung cancers and their degree of malignancy by FTIR, PCA-LDA analysis, and a physics-based computational model. <i>Talanta</i> , 2018, 186, 337-345.	2.9	61
403	Ocular Toxicity Profile of ST-162 and ST-168 as Novel Bifunctional MEK/PI3K Inhibitors. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2018, 34, 477-485.	0.6	3
406	Efficient Parameter Estimation Enables the Prediction of Drug Response Using a Mechanistic Pan-Cancer Pathway Model. <i>Cell Systems</i> , 2018, 7, 567-579.e6.	2.9	99
407	Expression of two non-mutated genetic elements is sufficient to stimulate oncogenic transformation of human mammary epithelial cells. <i>Cell Death and Disease</i> , 2018, 9, 1147.	2.7	10
408	Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors. <i>Oncotarget</i> , 2018, 9, 1641-1655.	0.8	25
409	MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3920.	1.8	24
410	Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7095-7107.	1.0	187
411	PARP10 promotes cellular proliferation and tumorigenesis by alleviating replication stress. <i>Nucleic Acids Research</i> , 2018, 46, 8908-8916.	6.5	59
412	Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells. <i>Nature Communications</i> , 2018, 9, 3212.	5.8	97
413	Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics. <i>Experimental Cell Research</i> , 2018, 371, 1-19.	1.2	59
414	An update of knowledge on cortactin as a metastatic driver and potential therapeutic target in oral squamous cell carcinoma. <i>Oral Diseases</i> , 2019, 25, 949-971.	1.5	22
415	Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. <i>Npj Precision Oncology</i> , 2019, 3, 18.	2.3	25
416	Investigation of Precise Molecular Mechanistic Action of Tobacco-Associated Carcinogen 'NNK' Induced Carcinogenesis: A System Biology Approach. <i>Genes</i> , 2019, 10, 564.	1.0	7
417	The Cell Cycle, Cytoskeleton and Cancer. <i>Learning Materials in Biosciences</i> , 2019, , 51-74.	0.2	1

#	ARTICLE	IF	CITATIONS
418	Double <i>PIK3CA</i> mutations in cis increase oncogenicity and sensitivity to PI3K inhibitors. <i>Science</i> , 2019, 366, 714-723.	6.0	185
419	MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells. <i>PLoS ONE</i> , 2019, 14, e0223225.	1.1	12
420	Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency. <i>Cancers</i> , 2019, 11, 1480.	1.7	31
421	Maintenance of the bladder cancer precursor urothelial hyperplasia requires FOXA1 and persistent expression of oncogenic HRAS. <i>Scientific Reports</i> , 2019, 9, 270.	1.6	7
422	Sparse discriminative latent characteristics for predicting cancer drug sensitivity from genomic features. <i>PLoS Computational Biology</i> , 2019, 15, e1006743.	1.5	4
423	Indenoisoquinoline Topoisomerase Inhibitors Strongly Bind and Stabilize the <i>MYC</i> Promoter G-Quadruplex and Downregulate <i>MYC</i> . <i>Journal of the American Chemical Society</i> , 2019, 141, 11059-11070.	6.6	66
424	Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics. , 2019, 202, 18-31.		37
426	Context-dependent genetic interactions in cancer. <i>Current Opinion in Genetics and Development</i> , 2019, 54, 73-82.	1.5	16
427	Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 929-936.	1.9	29
428	MicroRNA-374a Governs Aggressive Cell Behaviors of Glioma by Targeting Prokineticin 2. <i>Technology in Cancer Research and Treatment</i> , 2019, 18, 153303381882140.	0.8	5
429	Intratumoural Heterogeneity Underlies Distinct Therapy Responses and Treatment Resistance in Glioblastoma. <i>Cancers</i> , 2019, 11, 190.	1.7	39
430	The second genome: Effects of the mitochondrial genome on cancer progression. <i>Advances in Cancer Research</i> , 2019, 142, 63-105.	1.9	19
431	Transcriptional addiction in mixed lineage leukemia: new avenues for target therapies. <i>Blood Science</i> , 2019, 1, 50-56.	0.4	1
432	Reversion of tumor hepatocytes to normal hepatocytes during liver tumor regression in an oncogene transgenic zebrafish model. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	1.2	13
433	Dual specificity phosphatase 6 as a new therapeutic target candidate for epithelial ovarian cancer. <i>Annals of Translational Medicine</i> , 2019, 7, S373-S373.	0.7	1
434	Network-based Biased Tree Ensembles (NetBiTE) for Drug Sensitivity Prediction and Drug Sensitivity Biomarker Identification in Cancer. <i>Scientific Reports</i> , 2019, 9, 15918.	1.6	20
435	Chromatin Interactions and Regulatory Elements in Cancer: From Bench to Bedside. <i>Trends in Genetics</i> , 2019, 35, 145-158.	2.9	22
436	Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase. <i>Cancer Letters</i> , 2019, 443, 189-202.	3.2	18



#	ARTICLE	IF	CITATIONS
437	A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives. <i>Scientific Reports</i> , 2019, 9, 14.	1.6	28
438	Isolation and in silico prediction of potential drug-like compounds from <i>Anethum sowa</i> L. root extracts targeted towards cancer therapy. <i>Computational Biology and Chemistry</i> , 2019, 78, 242-259.	1.1	14
439	Single-Cell-Based In Silico Models: A Tool for Dissecting Tumor Heterogeneity. , 2019, , 130-143.		6
440	Identification and Therapeutic Intervention of Coactivated Anaplastic Lymphoma Kinase, Fibroblast Growth Factor Receptor 2, and Ephrin Typeâ€A Receptor 5 Kinases in Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 573-586.	3.6	12
441	Anti-cancer effect of toosendanin and its underlying mechanisms. <i>Journal of Asian Natural Products Research</i> , 2019, 21, 270-283.	0.7	30
442	Therapeutic Targeting of Cancer Cells. , 2020, , 420-430.e2.		0
443	Growth of cells, growth factors, and oncogenes. , 2020, , 87-104.		0
444	Acquired Resistance in Lung Cancer. <i>Annual Review of Cancer Biology</i> , 2020, 4, 279-297.	2.3	13
445	The ROS-KRAS-Nrf2 axis in the control of the redox homeostasis and the intersection with survival-apoptosis pathways: Implications for photodynamic therapy. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2020, 202, 111672.	1.7	35
446	Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality. <i>IScience</i> , 2020, 23, 101604.	1.9	14
447	Computational Drug Repositioning Identifies Potentially Active Therapies for Chordoma. <i>Neurosurgery</i> , 2021, 88, 428-436.	0.6	7
448	Causes of cancer: physical, chemical, biological carcinogens, and viruses. , 2020, , 607-641.		3
449	Cellular reprogramming to model and study epigenetic alterations in cancer. <i>Stem Cell Research</i> , 2020, 49, 102062.	0.3	7
450	Deep learning-based classification and interpretation of gene expression data from cancer and normal tissues. <i>International Journal of Data Mining and Bioinformatics</i> , 2020, 24, 121.	0.1	1
451	Development and implementation of the SUM breast cancer cell line functional genomics knowledge base. <i>Npj Breast Cancer</i> , 2020, 6, 30.	2.3	4
452	<p>Impact of Somatic Mutations in Non-Small-Cell Lung Cancer: A Retrospective Study of a Chinese Cohort</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 7427-7437.	0.9	2
453	Role of Poly [ADP-ribose] Polymerase 1 in Activating the Kirsten ras (KRAS) Gene in Response to Oxidative Stress. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6237.	1.8	13
454	Phosphorylation-Dependent Pin1 Isomerization of ATR: Its Role in Regulating ATRâ€™s Anti-apoptotic Function at Mitochondria, and the Implications in Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 281.	1.8	15

#	ARTICLE	IF	CITATIONS
455	Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. <i>Cancers</i> , 2020, 12, 1196.	1.7	65
456	Differential responses to kinase inhibition in FGFR2-addicted triple negative breast cancer cells: a quantitative phosphoproteomics study. <i>Scientific Reports</i> , 2020, 10, 7950.	1.6	10
457	An update on the implications of cyclin D1 in melanomas. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 788-805.	1.5	34
458	Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR. <i>Topics in Medicinal Chemistry</i> , 2020, , 155-201.	0.4	0
459	Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment. <i>Advances in Cancer Research</i> , 2020, 147, 1-57.	1.9	32
460	MET targeting: time for a rematch. <i>Oncogene</i> , 2020, 39, 2845-2862.	2.6	40
461	Evidence for immortality and autonomy in animal cancer models is often not provided, which causes confusion on key issues of cancer biology. <i>Journal of Cancer</i> , 2020, 11, 2887-2920.	1.2	4
462	High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 4302-4312.	3.2	10
463	Current developments of targeting the p53 signaling pathway for cancer treatment. , 2021, 220, 107720.		70
464	E1 Enzymes as Therapeutic Targets in Cancer. <i>Pharmacological Reviews</i> , 2021, 73, 1-56.	7.1	60
465	Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3 $\beta$ inhibitors targeting breast cancer: design, synthesis, biological evaluation, and <i>in silico</i> studies. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021, 36, 271-286.	2.5	52
466	Antitumor effects of novel mAbs against cationic amino acid transporter 1 (CAT1) on human CRC with amplified <i>CAT1</i> gene. <i>Cancer Science</i> , 2021, 112, 563-574.	1.7	14
467	NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted Therapy. <i>Clinical Lung Cancer</i> , 2021, 22, 1-5.	1.1	43
468	Models of Cancer Drug Discovery and Response to Therapy. , 2021, , 269-276.		0
469	Integrated molecular characterisation of the MAPK pathways in human cancers reveals pharmacologically vulnerable mutations and gene dependencies. <i>Communications Biology</i> , 2021, 4, 9.	2.0	32
470	Phenylboronic acid-functionalized polyaminoglycoside as an effective CRISPR/Cas9 delivery system. <i>Biomaterials Science</i> , 2021, 9, 7104-7114.	2.6	12
471	Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors. <i>Investigational New Drugs</i> , 2021, 39, 803-811.	1.2	18
472	Targeting Non-Oncogene Addiction for Cancer Therapy. <i>Biomolecules</i> , 2021, 11, 129.	1.8	10

#	ARTICLE	IF	CITATIONS
473	Drug delivery systems in cancer therapy. , 2021, , 423-454.		2
474	Nanomaterials Enhance the Immunomodulatory Effect of Molecular Targeted Therapy. International Journal of Nanomedicine, 2021, Volume 16, 1631-1661.	3.3	19
475	The conformation-specific Hsp90 inhibition interferes with the oncogenic RAF kinase adaptation and triggers premature cellular senescence, hence, acts as a tumor suppressor mechanism. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 118943.	1.9	3
476	Oncogenic functions and therapeutic targeting of EphA2 in cancer. Oncogene, 2021, 40, 2483-2495.	2.6	56
477	Prognostic and Clinicopathological Significance of CCND1/Cyclin D1 Upregulation in Melanomas: A Systematic Review and Comprehensive Meta-Analysis. Cancers, 2021, 13, 1314.	1.7	17
478	Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction. PLoS ONE, 2021, 16, e0249388.	1.1	2
479	Cancer as a form of life: Musings of the cancer and evolution symposium. Progress in Biophysics and Molecular Biology, 2021, 165, 120-139.	1.4	6
480	Mechanisms of breast cancer metastasis. Clinical and Experimental Metastasis, 2022, 39, 117-137.	1.7	27
481	Anti-IL-4Ralpha monoclonal antibody dupilumab mimics ulcerative colitis: a case report. BMC Gastroenterology, 2021, 21, 207.	0.8	10
482	Our Journey Beyond Sunset Boulevard: Evidence-Based Analysis of Tumor-Targeted Cancer Gene Therapy Shines a Critical Spotlight on Long-Term Cancer-Free Survival. , 0, , .		0
483	Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics, 2021, 20, 1246-1256.	1.9	18
484	Addiction to Golgi-resident PI4P synthesis in chromosome 1q21.3â€“amplified lung adenocarcinoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	12
485	The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer. Expert Opinion on Drug Discovery, 2021, 16, 1091-1103.	2.5	6
486	WNT5A inhibition alters the malignant peripheral nerve sheath tumor microenvironment and enhances tumor growth. Oncogene, 2021, 40, 4229-4241.	2.6	7
487	VRK1 Depletion Facilitates the Synthetic Lethality of Temozolomide and Olaparib in Glioblastoma Cells. Frontiers in Cell and Developmental Biology, 2021, 9, 683038.	1.8	9
488	D-Propranolol Impairs EGFR Trafficking and Destabilizes Mutant p53 Counteracting AKT Signaling and Tumor Malignancy. Cancers, 2021, 13, 3622.	1.7	5
489	Analysis of CCND1 protein and circulatory antioxidant enzyme activity association in oral squamous cell carcinoma. Saudi Journal of Biological Sciences, 2021, 28, 6987-6991.	1.8	8
490	Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors. Cancers, 2021, 13, 3531.	1.7	9

#	ARTICLE	IF	CITATIONS
491	Amivantamab: Treating EGFR Exon 20 Mutant Cancers With Bispecific Antibody-Mediated Receptor Degradation. <i>Journal of Clinical Oncology</i> , 2021, 39, 3403-3406.	0.8	8
492	Capturing cancer evolution using genetically engineered mouse models (GEMMs). <i>Trends in Cell Biology</i> , 2021, 31, 1007-1018.	3.6	20
493	In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK). <i>Investigational New Drugs</i> , 2022, 40, 68-80.	1.2	11
494	Potential therapies and diagnosis based on Golgi-targeted nano drug delivery systems. <i>Pharmacological Research</i> , 2022, 175, 105861.	3.1	22
495	Therapeutic Strategies Targeting Tumor Suppressor Genes in Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 3920.	1.7	8
496	Tilting MYC toward cancer cell death. <i>Trends in Cancer</i> , 2021, 7, 982-994.	3.8	12
497	A DNA dendrimer amplified electrochemical immunosensing method for highly sensitive detection of prostate specific antigen. <i>Analytica Chimica Acta</i> , 2021, 1186, 339083.	2.6	7
502	Relevance of the Concept of Oncogene Addiction to Hormonal Carcinogenesis and Molecular Targeting in Cancer Prevention and Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2008, 617, 3-13.	0.8	18
503	Anticancer Drug Discovery and Development. <i>Advances in Experimental Medicine and Biology</i> , 2008, 610, 19-42.	0.8	5
504	Signal Transduction Pathways as Therapeutic Targets in Cancer Therapy. , 2010, , 37-83.		2
505	Systems Medicine in Oncology: Signaling Network Modeling and New-Generation Decision-Support Systems. <i>Methods in Molecular Biology</i> , 2016, 1386, 181-219.	0.4	12
506	Systems Biology of Personalized Medicine. , 2009, , 615-630.		2
507	FGFR4 as a Biomarker in Squamous Cell Cancers of Mouth and Oropharynx. <i>Biomarkers in Disease</i> , 2015, , 809-826.	0.0	2
508	Principles of Molecularly Targeted Therapy: Present and Future. , 2008, , 485-500.		1
509	Primary ilioacaval leiomyosarcomas: The path beyond surgery. <i>European Journal of Surgical Oncology</i> , 2020, 46, 893-897.	0.5	8
513	New molecularly targeted therapies for lung cancer. <i>Journal of Clinical Investigation</i> , 2007, 117, 2740-2750.	3.9	180
514	Regulation of myeloproliferation and M2 macrophage programming in mice by Lyn/Hck, SHIP, and Stat5. <i>Journal of Clinical Investigation</i> , 2008, 118, 924-34.	3.9	63
515	Cotargeting survival signaling pathways in cancer. <i>Journal of Clinical Investigation</i> , 2008, 118, 3003-6.	3.9	106

#	ARTICLE	IF	CITATIONS
516	FAM83A and FAM83B: candidate oncogenes and TKI resistance mediators. <i>Journal of Clinical Investigation</i> , 2012, 122, 3048-3051.	3.9	45
517	Functional Characterization of Human Cancer-Derived TRKB Mutations. <i>PLoS ONE</i> , 2011, 6, e16871.	1.1	46
518	Efficient Elimination of Cancer Cells by Deoxyglucose-ABT-263/737 Combination Therapy. <i>PLoS ONE</i> , 2011, 6, e24102.	1.1	65
519	Establishment of HRASG12V Transgenic Medaka as a Stable Tumor Model for In Vivo Screening of Anticancer Drugs. <i>PLoS ONE</i> , 2013, 8, e54424.	1.1	10
520	A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma. <i>PLoS ONE</i> , 2015, 10, e0127246.	1.1	105
521	KDM6A addiction of cervical carcinoma cell lines is triggered by E7 and mediated by p21CIP1 suppression of replication stress. <i>PLoS Pathogens</i> , 2017, 13, e1006661.	2.1	31
522	A New Linkage between the Tumor Suppressor RKIP and Autophagy: Targeted Therapeutics. <i>Critical Reviews in Oncogenesis</i> , 2018, 23, 281-305.	0.2	15
523	Angiogenin contributes to bladder cancer tumorigenesis by DNMT3b-mediated MMP2 activation. <i>Oncotarget</i> , 2016, 7, 43109-43123.	0.8	24
524	Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases. <i>Oncotarget</i> , 2016, 7, 47848-47863.	0.8	43
525	STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL). <i>Oncotarget</i> , 2013, 4, 1093-1102.	0.8	32
526	Suppression of gain-of-function mutant p53 with metabolic inhibitors reduces tumor growth in vivo. <i>Oncotarget</i> , 2016, 7, 77664-77682.	0.8	7
527	An XIST-related small RNA regulates KRAS G-quadruplex formation beyond X-inactivation. <i>Oncotarget</i> , 2016, 7, 86713-86729.	0.8	4
528	Identification of anaplastic lymphoma kinase as a potential therapeutic target in Basal Cell Carcinoma. <i>Oncotarget</i> , 2013, 4, 2237-2248.	0.8	20
529	Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells. <i>Oncotarget</i> , 2017, 8, 28971-28989.	0.8	11
530	Human T cell leukemia virus type 1 (HTLV-1) and oncogene or oncomiR addiction?. <i>Oncotarget</i> , 2010, 1, 453-456.	0.8	19
531	The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo. <i>Oncotarget</i> , 2019, 10, 6323-6333.	0.8	9
532	Advances in dynamic modeling of colorectal cancer signaling-network regions, a path toward targeted therapies. <i>Oncotarget</i> , 2015, 6, 5041-5058.	0.8	24
533	Targeting Notch to overcome radiation resistance. <i>Oncotarget</i> , 2016, 7, 7610-7628.	0.8	50

#	ARTICLE	IF	CITATIONS
534	Diagnostic molecular techniques in haematology: recent advances. <i>Annals of Translational Medicine</i> , 2018, 6, 242-242.	0.7	7
535	Histone Lysine-Specific Methyltransferases and Demethylases in Carcinogenesis: New Targets for Cancer Therapy and Prevention. <i>Current Cancer Drug Targets</i> , 2013, 13, 558-579.	0.8	65
536	Targeting late SV40 factor: Is the achilles heel of hepatocarcinogenesis revealed?. <i>World Journal of Gastroenterology</i> , 2012, 18, 6709.	1.4	5
537	Personalized targeted therapy in advanced non-small cell lung cancer. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, S56-S60.	0.6	42
538	Somatic DNA mutation analysis in targeted therapy of solid tumours. <i>Translational Pediatrics</i> , 2015, 4, 125-38.	0.5	19
539	Molecularly targeted therapies in non-small cell lung cancer: The evolving role of tyrosine kinase inhibitors. <i>Indian Journal of Cancer</i> , 2019, 56, 23.	0.2	6
540	Present Status and Problems on Molecular Targeted Therapy of Cancer. <i>Cancer Research and Treatment</i> , 2012, 44, 1-10.	1.3	24
541	The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy. <i>Cancer Research and Treatment</i> , 2019, 51, 169-177.	1.3	3
542	Clinical significance of MET in gastric cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2015, 7, 317.	0.8	36
543	Cancer stem cells and addicted cancer cells. <i>Oncology Discovery</i> , 2013, 1, 7.	0.5	3
544	Mutational analysis of driver genes with tumor suppressive and oncogenic roles in gastric cancer. <i>PeerJ</i> , 2017, 5, e3585.	0.9	7
545	Liquid Biopsy. <i>UNIPA Springer Series</i> , 2021, , 99-122.	0.1	0
546	Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways. , 2008, , 317-365.		0
547	Molecular Signatures of Drug Resistance. , 2009, , 271-294.		0
548	mTOR and Cancer Therapy: General Principles. , 2009, , 113-131.		0
549	EGFR and HER2: Relevance in Renal Cell Carcinoma. , 2009, , 287-303.		0
550	The Future of Lung Cancer. , 2010, , 503-514.		0
551	Glioblastoma Multiforme: Molecular Basis of Resistance to Erlotinib. , 2011, , 259-267.		0

#	ARTICLE	IF	CITATIONS
552	Rational Combination of Targeted Agents to Overcome Cancer Cell Resistance. , 2011, , 171-195.		1
553	Resistance to Targeted Therapies As a Result of Mutation(s) in the Target. , 2011, , 1-31.		0
554	The Dynamics of the Cell Signaling Network; Implications for Targeted Therapies. , 2011, , 33-53.		0
555	Oncogene Addiction. , 2011, , 2616-2622.		1
556	Breast Cancer Targeted Therapies. , 2011, , 552-565.		0
557	Soft Tissue "Small Round Blue Cell Tumors" of Childhood. , 2012, , 169-197.		0
560	Challenges for Pain Management in the Twenty-First Century. , 2013, , 263-278.		0
561	Therapeutic Targeting of Cancer Cells. , 2014, , 423-433.e2.		1
565	Transcription Factors Synergistically Activated at the Crossing of the Restriction Point between G1 and S Cell Cycle Phases. Pathologic Gate Opening during Multi-Hit Malignant Transformation. Nuclear Receptor Research, 2016, 3, .	2.5	0
566	Oncogene Addiction. , 2017, , 3207-3214.		0
568	6. La "médecine personnalisée en cancérologie": vers une complexification des stratégies thérapeutiques?. , 2018, , 87-104.		0
570	Therapeutic Use of Inorganic Nanomaterials in Malignant Diseases. Environmental Chemistry for A Sustainable World, 2020, , 47-87.	0.3	0
571	Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality. SSRN Electronic Journal, 0, , .	0.4	0
574	Estrogen Receptor Positive Breast Cancer: 8p11-p12 Amplicon and Therapeutic Response. , 2021, , .		0
575	Validation of Superiority of p40 over p63 in Differentiating Squamous Cell Carcinoma and Adenocarcinoma Lung. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 535-542.	0.1	2
576	Non-Small Cell Lung Cancer with Brain Metastasis: Role of Epidermal Growth Factor Receptor Gene Mutation. , 2008, , 371-387.		0
577	Multiplexed Protein Biomarker Detection with Microfluidic Electrochemical Immunoarrays. Methods in Molecular Biology, 2021, 2237, 69-82.	0.4	2
578	The role of oncogenes in gastrointestinal cancer. Gastrointestinal Cancer Research: GCR, 2010, , S2-S15.	0.8	3

#	ARTICLE	IF	CITATIONS
579	Human T cell leukemia virus type 1 (HTLV-1) and oncogene or oncomiR addiction?. <i>Oncotarget</i> , 2010, 1, 453-6.	0.8	14
580	The diverse and complex roles of radiation on cancer treatment: therapeutic target and genome maintenance. <i>American Journal of Cancer Research</i> , 2012, 2, 372-82.	1.4	6
582	Enhancement of taxol, doxorubicin and zoledronate anti-proliferation action on triple-negative breast cancer cells by a PTHrP blocking monoclonal antibody. <i>American Journal of Cancer Research</i> , 2013, 3, 500-8.	1.4	11
583	Approaches to identifying synthetic lethal interactions in cancer. <i>Yale Journal of Biology and Medicine</i> , 2015, 88, 145-55.	0.2	32
584	Assessment of epidermal growth factor receptor status in glioblastomas. <i>Asia Oceania Journal of Nuclear Medicine and Biology</i> , 2013, 1, 47-52.	0.1	1
587	Targeting Oncogene Addiction for Cancer Therapy. , 0, , .		0
588	Crescent-shaped Carbazole Derivatives as Light-up Fluorescence Probes for G-quadruplex DNA and Live Cell Imaging. <i>Chemistry and Biodiversity</i> , 2022, 19, .	1.0	5
589	CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma. <i>Cancer Research</i> , 2022, 82, 1110-1127.	0.4	3
590	Super-Enhancers Dysregulations in Hematological Malignancies. <i>Cells</i> , 2022, 11, 196.	1.8	5
591	Reactive Oxygen Species: Induced Epigenetic Modification in the Expression Pattern of Oncogenic Proteins. , 2022, , 1-16.		0
592	LKB1 drives stasis and C/EBP-mediated reprogramming to an alveolar type II fate in lung cancer. <i>Nature Communications</i> , 2022, 13, 1090.	5.8	5
594	Kanserde Hedefe Ynelik Tedavi: PI3K/Akt/mTOR nhibitrleri. <i>Arsiv Kaynak Tarama Dergisi</i> , 2022, 31, 15-20.	0.1	0
595	The human AP-endonuclease 1 (APE1) is a DNA G-quadruplex structure binding protein and regulates <i>KRAS</i> expression in pancreatic ductal adenocarcinoma cells. <i>Nucleic Acids Research</i> , 2022, 50, 3394-3412.	6.5	23
598	Identification of 3-(piperazinylmethyl)benzofuran derivatives as novel type II CDK2 inhibitors: design, synthesis, biological evaluation, and <i>in silico</i> insights. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 1227-1240.	2.5	15
600	The oncogene-dependent resistance to reprogramming unveils cancer therapeutic targets. <i>Cell Reports</i> , 2022, 39, 110721.	2.9	8
601	ISL2 is a putative tumor suppressor whose epigenetic silencing reprograms the metabolism of pancreatic cancer. <i>Developmental Cell</i> , 2022, 57, 1331-1346.e9.	3.1	9
602	Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3235-3241.	3.2	6
604	Dual therapeutic approach to modulate Glycogen Synthase kinase 3 beta (GSK-3) and inhibitor of nuclear factor kappa kinase-beta (IKK-2) receptors by <i>in silico</i> designing of inhibitors. <i>Journal of Molecular Graphics and Modelling</i> , 2022, 115, 108225.	1.3	1



#	ARTICLE	IF	CITATIONS
605	Targeting MET amplification in Gastro-oesophageal (GO) malignancies and overcoming MET inhibitor resistance: challenges and opportunities. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, 16, 601-624.	1.4	0
607	Reactive Oxygen Species: Induced Epigenetic Modification in the Expression Pattern of Oncogenic Proteins. , 2022, , 1357-1372.		0
608	White Paper: Mimetics of Class 2 Tumor Suppressor Proteins as Novel Drug Candidates for Personalized Cancer Therapy. <i>Cancers</i> , 2022, 14, 4386.	1.7	7
609	The 8p11 myeloproliferative syndrome: Genotypic and phenotypic classification and targeted therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
610	Idiopathic pulmonary fibrosis and lung cancer: targeting the complexity of the pharmacological interconnection. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 1043-1055.	1.0	1
612	<sc>MET</sc> kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with <sc>NTRK1</sc> or <sc>ROS1</sc> rearrangements. <i>Cancer Medicine</i> , 2023, 12, 5809-5820.	1.3	4
613	Defektif Homolog Rekombinasyon DNA Tamiri ve PARP Ğnhibisyonu ArasĞndaki Sentetik Letal EtkileĞim. <i>Journal of the Institute of Science and Technology</i> , 0, , 2459-2475.	0.3	0
614	Formulation Development, Optimization, and Characterization of Entrectinib-Loaded Supersaturable Self-Nanoemulsifying Drug Delivery Systems. <i>BioNanoScience</i> , 2023, 13, 521-540.	1.5	1
615	TumorĞderived insulinĞlike growth factorĞbinding proteinĞ1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors. <i>Cancer Communications</i> , 2023, 43, 415-434.	3.7	2
616	Exploring the adsorption performance of doped graphene quantum dots as anticancer drug carriers for cisplatin by DFT, PCM, and COSMO approaches. <i>Structural Chemistry</i> , 0, , .	1.0	2
617	New therapies for clear cell ovarian carcinoma. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 385-393.	1.2	6
618	Targeted therapy for lung cancer: Beyond EGFR and ALK. <i>Cancer</i> , 2023, 129, 1803-1820.	2.0	9
632	Molecular docking and pharmacophore analysis of trisindoline 1 against human topoisomerase II and human derived growth factor. <i>AIP Conference Proceedings</i> , 2024, , .	0.3	0